DP 5541
Alternative Names: 18F-AzaFol; DP-5541; ITM-55DLatest Information Update: 28 Aug 2025
At a glance
- Originator Isotopen Technologien Munchens
- Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Non-small cell lung cancer; Ovarian cancer; Solid tumours
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Diagnosis) in Germany (Parenteral)
- 28 Aug 2025 No recent reports of development identified for phase-I development in Ovarian-cancer(Diagnosis) in Germany (Parenteral)
- 28 Mar 2024 Insel Gruppe AG, University Hospital Bern plans a phase II trial for Giant cell arteritis (Diagnosis, In adults, In the elderly) in Switzerland (Parenteral) (NCT06335888)